RDC-0313 + Buprenorphine
ALK33-008
Phase 1 small_molecule completed
Quick answer
RDC-0313 + Buprenorphine for Substance-Related Disorders is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Substance-Related Disorders
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed